Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy.

Matrix metalloproteinase (MMP)-1 and MMP-3 levels were measured in serum samples from rheumatoid arthritis (RA) patients undergoing a double-blinded placebo-controlled trial with the chimaeric anti-tumour necrosis factor (TNF)-alpha antibody cA2. Both MMP-1 (P < 0.015), but to a larger extent...

Cijeli opis

Bibliografski detalji
Glavni autori: Brennan, F, Browne, K, Green, P, Jaspar, J, Maini, R, Feldmann, M
Format: Journal article
Jezik:English
Izdano: 1997